{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:26:11Z","timestamp":1792063571993,"version":"4.4.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ygyno.2016.10.011","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T03:51:58Z","timestamp":1476676318000},"page":"466-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study"],"prefix":"10.1016","volume":"143","author":[{"given":"Pamela T.","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell R.","family":"Broaddus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark F.","family":"Munsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Schmandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Ramondetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2016.10.011_bb0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-008-1157-y","article-title":"Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"52","author":"Nathan","year":"2009","journal-title":"Diabetologia"},{"issue":"7503","key":"10.1016\/j.ygyno.2016.10.011_bb0010","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"issue":"9","key":"10.1016\/j.ygyno.2016.10.011_bb0015","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes","volume":"32","author":"Libby","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ygyno.2016.10.011_bb0020","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2009.04.013","article-title":"Antidiabetic therapies affect risk of pancreatic cancer","volume":"137","author":"Li","year":"2009","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.ygyno.2016.10.011_bb0025","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","article-title":"Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer","volume":"27","author":"Jiralerspong","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2016.10.011_bb0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cncr.27706","article-title":"Metformin intake is associated with better survival in ovarian cancer: a case-control study","volume":"119","author":"Kumar","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2016.10.011_bb0035","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev. Res."},{"issue":"4","key":"10.1016\/j.ygyno.2016.10.011_bb0040","first-page":"355 e1-7","article-title":"Prospective evaluation of insulin resistance among endometrial cancer patients","volume":"204","author":"JK","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2016.10.011_bb0045","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1055-9965.EPI-06-0751","article-title":"Diabetes and risk of endometrial cancer: a population-based prospective cohort study","volume":"16","author":"Friberg","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"1","key":"10.1016\/j.ygyno.2016.10.011_bb0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2009.09.024","article-title":"Metformin is a potent inhibitor of endometrial cancer cell proliferation\u2013implications for a novel treatment strategy","volume":"116","author":"Cantrell","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2016.10.011_bb0055","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1158\/1535-7163.MCT-13-0439","article-title":"Another surprise from metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy","volume":"12","author":"Iglesias","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.ygyno.2016.10.011_bb0060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ygyno.2014.06.014","article-title":"Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer","volume":"134","author":"Laskov","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2016.10.011_bb0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cam4.353","article-title":"Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer","volume":"4","author":"Schuler","year":"2015","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.ygyno.2016.10.011_bb0070","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10549-011-1612-1","article-title":"Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial","volume":"128","author":"Hadad","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.ygyno.2016.10.011_bb0075","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s10549-012-2223-1","article-title":"Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study","volume":"135","author":"Niraula","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"21","key":"10.1016\/j.ygyno.2016.10.011_bb0080","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2011.39.3769","article-title":"Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial","volume":"30","author":"Bonanni","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.10.011_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2015.01.391","article-title":"The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts","author":"Al Hilli","year":"2015","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816314834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816314834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T13:37:19Z","timestamp":1620826639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816314834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0090825816314834"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.10.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}